Reducing treatment toxicity in Waldenström macroglobulinemia

References

• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016 May 19;127(20):2375–2390.
   PubMed Web of Science ®Google Scholar
• Bustoros M, Sklavenitis-Pistofidis R, Kapoor P, et al. Progression risk stratification of asymptomatic Waldenstrom macroglobulinemia. J Clin Oncol. 2019 Jun 1;37(16):1403–1411.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom’s macroglobulinemia: consensus panel recommendations from the second international workshop on Waldenstrom’s macroglobulinemia. Semin Oncol. 2003 Apr;30(2):116–120.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Advani RH, Branagan AR, et al. Consensus treatment recommendations from the tenth international workshop for Waldenstrom macroglobulinaemia. Lancet Haematol. 2020 Nov;7(11):e827–e837.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013 Apr 6;381(9873):1203–1210.
   PubMed Web of Science ®Google Scholar
• Treon SP, Hanzis C, Tripsas C, et al. Bendamustine therapy in patients with relapsed or refractory Waldenstrom’s macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):133–135.
   PubMed Web of Science ®Google Scholar
• Tedeschi A, Picardi P, Ferrero S, et al. Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenstrom macroglobulinemia. Leuk Lymphoma. 2015;56(9):2637–2642.
   PubMed Web of Science ®Google Scholar
• Paludo J, Abeykoon JP, Shreders A, et al. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstrom macroglobulinemia. Ann Hematol. 2018 Aug;97(8):1417–1425.
   PubMed Web of Science ®Google Scholar
• Treon SP, Branagan AR, Ioakimidis L, et al. Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia. Blood. 2009 Apr 16;113(16):3673–3678.
   PubMed Web of Science ®Google Scholar
• Leblond V, Johnson S, Chevret S, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol. 2013 Jan 20;31(3):301–307.
   PubMed Web of Science ®Google Scholar
• Tamburini J, Levy V, Chaleteix C, et al. Fludarabine plus cyclophosphamide in Waldenstrom’s macroglobulinemia: results in 49 patients. Leukemia. 2005 Oct;19(10):1831–1834.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Gustine JN, Meid K, et al. Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenstrom macroglobulinaemia. Br J Haematol. 2018 Apr;181(1):77–85.
   PubMed Web of Science ®Google Scholar
• Auer RL, Owen RG, D’Sa S, et al. Subcutaneous bortezomib, cyclophosphamide and rituximab (BCR) versus fludarabine, cyclophosphamide and rituximab (FCR) for initial therapy of WaldenstrőM’s macroglobulinemia: a randomised phase II study. Blood. 2016;128(22):618.
   Web of Science ®Google Scholar
• Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenström’s macroglobulinemia: a phase II study of the National Cancer Institute of Canada clinical trials group. J clin oncol. 2007;25(12):1570–1575.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Treatment of relapsed or refractory Waldenstrom’s macroglobulinemia with bortezomib. Haematologica. 2005 Dec;90(12):1655–1658.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Hong F, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010 Mar 10;28(8):1422–1428.
   PubMed Web of Science ®Google Scholar
• Leblebjian H, Noonan K, Paba-Prada C, et al. Cyclophosphamide, bortezomib, and dexamethasone combination in Waldenstrom macroglobulinemia. Am J Hematol. 2015 Jun;90(6):E122–3.
   PubMed Web of Science ®Google Scholar
• Treon SP, Hunter ZR, Matous J, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom’s macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res. 2007 Jun 1;13(11):3320–3325.
   PubMed Web of Science ®Google Scholar
• Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180 [Clinical trial multicenter study research support, N.I.H., extramural research support, Non-U.S. Gov’t]. J Clin Oncol. 2009 Aug 10;27(23):3830–3835.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Garcia-Sanz R, Gavriatopoulou M, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European myeloma network (EMN). Blood. 2013 Nov 7;122(19):3276–3282.
   PubMed Web of Science ®Google Scholar
• Merz M, Salwender H, Haenel M, et al. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial. Haematologica. 2015 Jul;100(7):964–969.
   PubMed Web of Science ®Google Scholar
• Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011 May;12(5):431–440.
   PubMed Web of Science ®Google Scholar
• Buske C, Dimopoulos MA, Grunenberg A, et al. Bortezomib in combination with dexamethasone, rituximab and cyclophosphamide (B-DRC) as first-line treatment of Waldenstrom’s macroglobulinemia: results of a prospectively randomized multicenter European phase II trial. Blood. 2020;136(Supplement 1):26.
   Google Scholar
• Castillo JJ, Meid K, Flynn CA, et al. Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenstrom macroglobulinemia: long-term follow-up. Blood Adv. 2020 Aug 25;4(16):3952–3959.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Meid K, Gustine JN, et al. Prospective clinical trial of ixazomib, dexamethasone, and rituximab as primary therapy in Waldenstrom macroglobulinemia. Clin Cancer Res. 2018 Jul 15;24(14):3247–3252.
   PubMed Web of Science ®Google Scholar
• Kersten MJ, Minnema MC, Vos JM, et al. Ixazomib, rituximab and dexamethasone (IRD) in patients with relapsed or progressive Waldenstrom’s macroglobulinemia: results of the prospective phase I/II HOVON 124/Ecwm-R2 Trial. Blood. 2019;134(Supplement_1):344.
   Google Scholar
• Treon SP, Tripsas CK, Meid K, et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom’s macroglobulinemia. Blood. 2014 Jul 24;124(4):503–510.
   PubMed Web of Science ®Google Scholar
• Waxman AJ, Clasen S, Hwang WT, et al. Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis. JAMA Oncol. 2018 Mar 8;4(3):e174519.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Rue M, Blood E, et al. Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group study (E3A98). Leuk Lymphoma. 2004 Oct;45(10):2047–2055.
   PubMed Web of Science ®Google Scholar
• Treon SP, Emmanouilides C, Kimby E, et al. Extended rituximab therapy in Waldenstrom’s macroglobulinemia. Ann Oncol. 2005 Jan;16(1):132–138.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Fonseca R, Greipp PR, et al. Initial immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group study. Cancer. 2004;101(11):2593–2598.
   PubMed Web of Science ®Google Scholar
• Treon SP, Branagan AR, Hunter Z, et al. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom’s macroglobulinemia. Ann Oncol. 2004 Oct;15(10):1481–1483.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Uslan DZ, Call TG, et al. Initial increase in the cryoglobulin level after rituximab therapy for type II cryoglobulinemia secondary to Waldenstrom macroglobulinemia does not indicate failure of response. Am J Hematol. 2004;77(4):329–330.
   PubMed Web of Science ®Google Scholar
• Noronha V, Fynan TM, Duffy T. Flare in neuropathy following rituximab therapy for Waldenstrom’s macroglobulinemia. J Clin Oncol. 2006 Jan 1;24(1):e3.
   PubMedGoogle Scholar
• Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 trial of Ibrutinib plus rituximab in Waldenstrom’s macroglobulinemia. N Engl J Med. 2018 Jun 21;378(25):2399–2410.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Kanan S, Meid K, et al. Rituximab intolerance in patients with Waldenstrom macroglobulinaemia. Br J Haematol. 2016 Aug;174(4):645–648.
   PubMed Web of Science ®Google Scholar
• Furman RR, Eradat HA, DiRienzo CG, et al. Once-weekly ofatumumab in untreated or relapsed Waldenstrom’s macroglobulinaemia: an open-label, single-arm, phase 2 study. Lancet Haematol. 2017 Jan;4(1):e24–e34.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Waldenstrom macroglobulinemia (Version 1.2021) [Cited 2021 Jan 31]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/waldenstroms.pdf
   Google Scholar
• Tomowiak C, Desseaux K, Poulain S, et al. Open label non-randomized phase ii study exploring «Chemo-Free » treatment association with idelalisib + obinutuzumab in patients with relapsed/refractory (R/R) Waldenstrom’s macroglobulinemia (MW), a Filo trial: results of the intermediary analysis of the induction phase. Blood. 2019;134(Supplement_1):346.
   Google Scholar
• Garcia-Munoz R, Quero C, Perez-Persona E, et al. Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study. Br J Haematol. 2020 Mar;188(5):661–673.
   PubMed Web of Science ®Google Scholar
• Lugtenburg P, Avivi I, Berenschot H, et al. Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. Haematologica. 2017 Nov;102(11):1913–1922.
   PubMed Web of Science ®Google Scholar
• Rummel M, Kim TM, Aversa F, et al. Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab). Ann Oncol. 2017 Apr 1;28(4):836–842.
   PubMed Web of Science ®Google Scholar
• Treon SP, Xu L, Hunter Z. MYD88 mutations and response to Ibrutinib in Waldenstrom’s macroglobulinemia. N Engl J Med. 2015 Aug 6;373(6):584–586.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Trotman J, Tedeschi A, et al. Ibrutinib for patients with rituximab-refractory Waldenstrom’s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017 Feb;18(2):241–250.
   PubMed Web of Science ®Google Scholar
• Treon SP, Gustine J, Meid K, et al. Ibrutinib monotherapy in symptomatic, treatment-naive patients with Waldenstrom macroglobulinemia. J Clin Oncol. 2018 Sep 20;36(27):2755–2761.
   PubMed Web of Science ®Google Scholar
• Thompson PA, Levy V, Tam CS, et al. Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study. Br J Haematol. 2016 Nov;175(3):462–466.
   PubMed Web of Science ®Google Scholar
• Gustine JN, Meid K, Dubeau TE, et al. Atrial fibrillation associated with ibrutinib in Waldenstrom macroglobulinemia. Am J Hematol. 2016 Jun;91(6):E312–3.
   PubMed Web of Science ®Google Scholar
• Caron F, Leong DP, Hillis C, et al. Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis. Blood Adv. 2017 May 9;1(12):772–778.
   PubMed Web of Science ®Google Scholar
• Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenstrom’s macroglobulinemia. N Engl J Med. 2015 Apr 9;372(15):1430–1440.
   PubMed Web of Science ®Google Scholar
• Levade M, David E, Garcia C, et al. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood. 2014 Dec 18;124(26):3991–3995.
   PubMed Web of Science ®Google Scholar
• Janssen P. Imbruvica product monograph 2020 [2020 Nov 30]. Available from: https://www.imbruvica.com/files/prescribing-information.pdf
   Google Scholar
• De Jong J, Skee D, Murphy J, et al. Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants. Pharmacol Res Perspect. 2015 Aug;3(4):e00156.
   PubMed Web of Science ®Google Scholar
• Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015 Dec 17;373(25):2425–2437.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Gustine JN, Meid K, et al. Ibrutinib withdrawal symptoms in patients with Waldenstrom macroglobulinemia. Haematologica. 2018 Jul;103(7):e307–e310.
   PubMed Web of Science ®Google Scholar
• Tam CS, Opat S, D’Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study. Blood. 2020 Oct 29;136(18):2038–2050.
   PubMed Web of Science ®Google Scholar
• Owen RG, McCarthy H, Rule S, et al. Acalabrutinib monotherapy in patients with Waldenstrom macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematol. 2020 Feb;7(2):e112–e121.
   PubMed Web of Science ®Google Scholar
• Awan FT, Schuh A, Brown JR, et al. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv. 2019 May 14;3(9):1553–1562.
   PubMed Web of Science ®Google Scholar
• Wang M, Shah NN, Alencar AJ, et al. LOXO-305, A next generation, highly selective, non-covalent BTK inhibitor in previously treated mantle cell lymphoma, Waldenström’s macroglobulinemia, and other non-Hodgkin lymphomas: results from the phase 1/2 BRUIN study. Blood. 2020;136(Supplement 1):8–10.
   PubMedGoogle Scholar
• Woyach J, Stephens DM, Flinn IW, et al. Final results of phase 1, dose escalation study evaluating ARQ 531 in patients with relapsed or refractory B-cell lymphoid malignancies. Blood. 2019;134(Supplement_1):4298.
   Google Scholar
• Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia. N Engl J Med. 2012 Aug 30;367(9):826–833.
   PubMed Web of Science ®Google Scholar
• Yang G, Zhou Y, Liu X, et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia. Blood. 2013 Aug 15;122(7):1222–1232.
   PubMed Web of Science ®Google Scholar
• Gunaratne M, Sahakian AJ, Abeykoon JP, et al. Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia. Leuk Lymphoma. 2021 Feb;62(2):308-315.
   PubMed Web of Science ®Google Scholar